Ultrafiltration Therapy for Heart Failure: Balancing Likely Benefits against Possible Risks

Area of Science:

• Cardiology
• Nephrology
• Critical Care Medicine

Background:

• Heart failure (HF) presents significant public health challenges due to high prevalence, morbidity, mortality, and costs.
• Current treatments for acute decompensated heart failure (ADHF) have limitations in efficacy, safety, and patient experience.
• Growing interest exists in extracorporeal isolated ultrafiltration (EUF) as a therapeutic option for ADHF.

Purpose of the Study:

• To review the mechanistic aspects of ultrafiltration therapy in ADHF.
• To critically evaluate major clinical trials investigating ultrafiltration for ADHF.
• To discuss the clinical relevance of renal dysfunction and decongestion endpoints in ultrafiltration trials.

Main Methods:

• Review of mechanistic aspects of ultrafiltration therapy.
• Critical overview of landmark clinical trials on ultrafiltration in ADHF.
• Analysis of safety and efficacy endpoints, including renal function and fluid status.

Main Results:

• Ultrafiltration therapy is being explored for ADHF due to limitations of conventional treatments.
• Key trial endpoints include renal dysfunction and decongestion, with emerging concepts challenging traditional views.
• Evidence is limited, precluding universal guidelines, necessitating individualized risk-benefit analysis.

Conclusions:

• Ultrafiltration therapy for ADHF requires careful balancing of potential benefits against risks.
• Customization of ultrafiltration rates and collaborative programs involving nephrology expertise are suggested.
• Further evidence is needed to establish consensus guidelines for ultrafiltration in ADHF.